Novartis has agreed to pay $245M to settle a lawsuit claiming the company attempted to delay the launch of generic copies of its Exforge blood-pressure medicine, Marthe Fourcade of Bloomberg reports. If the settlement is approved by a judge, it will resolve all outstanding claims on the matter for Novartis, Bloomberg added, citing an emailed statement made by the company. Reference Link
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on NVS:
- Sandoz Canada supports Ontario policy change on biosimilars
- Novartis call volume above normal and directionally bullish
- Harrow Health signs binding agreement to acquire rights to ophthalmic products
- Cantor biotech/biopharma analysts hold an analyst/industry conference call
- Novartis reports Phase 3 APPLY-PNH trial met both primary endpoints